Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2017-04-30 Investor Presentation
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Investor Day - Presentation 110 pages 15.0MB
Investor Presentation Classification · 95% confidence The document is titled 'Mayne Pharma Group Limited - Investor Day 1 May 2017' and contains detailed financial and operational information including revenue, EBITDA, R&D spend, business divisions, market analysis, and forward-looking statements. It is a comprehensive presentation aimed at investors, covering company strategy, market position, and financial performance. The content is typical of an investor presentation rather than a formal regulatory filing like an annual report or earnings release. There is no indication that this is a transcript, audit report, or regulatory announcement. The length (15,000 characters) and detailed financial data support classification as an Investor Presentation.
2017-04-30 English
Mayne Pharma to host Investor Day on May 1st, 2017 1
Investor Presentation Classification · 85% confidence The document is an ASX announcement about Mayne Pharma hosting an Investor Day event on May 1, 2017. It describes the event details, including a webcast and presentation by the CEO and leadership team, focusing on the company's growth strategy. There is no financial data, report content, or detailed analysis included. The document is short (2055 characters) and serves as an announcement for an upcoming investor presentation event rather than the presentation itself or a financial report. Therefore, it fits best under the category of Investor Presentation (IP) as it relates to a detailed presentation for investors focusing on financials, strategy, and market position, even though the actual presentation content is not included here, the announcement is about the event hosting the presentation.
2017-04-25 English
Becoming a substantial holder 3 pages 290.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 filed under the Corporations Act 2001, titled 'Notice of Initial Substantial Holder.' It details the substantial shareholding interests, voting power, relevant interests, registered holders, and consideration paid for shares by the substantial holder and associates. This type of filing is a notification of a major shareholding change, specifically the initial substantial holder notice. It is not a financial report, earnings release, or management report. It is a regulatory filing related to major shareholding notifications. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notice, not just an announcement or certification.
2017-04-10 English
Appendix 3B 9 pages 312.6KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of new shares, including the number of securities issued, issue price, purpose of the issue, and details about employee options. The document references compliance with ASX (Australian Securities Exchange) rules and includes a quotation agreement section. This type of document is a formal announcement related to capital raising and securities issuance rather than a financial report or management discussion. It fits the category of Capital/Financing Update (CAP) because it provides updates on company fundraising and capital structure changes. The document is lengthy (over 13,000 characters) and contains substantive details about the securities issued, which supports a high confidence classification as CAP.
2017-04-09 English
Appendix 3B 9 pages 716.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issuance of new securities, specifically fully paid ordinary shares and employee options under an employee share option plan. It includes detailed information about the class of securities issued, number of securities, issue price, purpose of the issue (long-term incentive), and compliance with ASX listing rules. The document also contains a quotation agreement section for the securities to be quoted on the ASX. This type of document is a formal announcement of a new share issue and application for quotation of additional securities, which aligns with the definition of a Share Issue/Capital Change announcement. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes.
2017-03-27 English
Change of Director's Interest Notice 2 pages 603.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares acquired and disposed, nature of interest, and dates of changes. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements, earnings data, or other report types. Therefore, it fits the definition of Director's Dealing (DIRS). The document length is 3474 characters, which is typical for such notices and not a report publication announcement or regulatory filing. Confidence is high due to clear identification of director share transactions and compliance with ASX rules for director interest disclosures.
2017-03-16 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.